Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study Combining Humanised Anti-CD20 (Veltuzumab), Anti-CD22 (Epratuzumab) and Both Monoclonal Antibodies With Intensive Chemotherapy in Adults With Recurrent or Refractory B-precursor Acute Lymphoblastic Leukaemia (ALL)

NCT01279707 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT01279707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01279707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study Combining Humanised Anti-CD20 (Veltuzumab), Anti-CD22 (Epratuzumab) and Both Monoclonal Antibodies With Intensive Chemotherapy in Adults With Recurrent or Refractory B-precursor Acute Lymphoblastic Leukaemia (ALL)
Lead sponsor
Queen Mary University of London
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 31, 2010
Completion date
August 31, 2014
Enrollment
55 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or refractory b cell acute lymphoblastic leukaemia